29 results
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
community necessary for commercial success.
Even if our products receive marketing approval, if needed, they may nonetheless fail to gain sufficient … market acceptance by physicians, patients, third-party payors, and others in the medical community. If we do not generate significant product revenues
POS AM
BIAF
BioAffinity Technologies Inc
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial success.
Even if our … payors, and others in the medical community. If we do not generate significant product revenues, we may not become profitable. The degree of market
424B5
h1gp9z9t
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
kc03f gv65f
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
6kw9v56 mn3
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
awwg wls9mwt36
16 Nov 23
Shelf registration
5:23pm
8-K
EX-99.3
t620xa2w6f hg5865f
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
8-K
EX-10.1
6e9as6 7k
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
8-K
EX-10.3
9ie5rjh4sbvsq kq
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
8-K
EX-10.4
pz9vn
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
DRS
wj95lxp
14 Aug 23
Draft registration statement
12:00am
8-K
EX-99.1
wg7vq3v9p5wq 13
1 May 23
Departure of Directors or Certain Officers
3:04pm
DEF 14A
6t4w 7k4fjap
1 May 23
Definitive proxy
2:55pm
PRE 14A
zlrj7
19 Apr 23
Preliminary proxy
9:56pm